Investor Presentaiton

For personal use only Source and use of funds Advancing and expanding the therapeutic (Tx) and diagnostic (Dx) portfolio . • • Complete ProstACT prostate cancer therapy studies (TLX591) including ProstACT GLOBAL Phase III study Complete STARLITE 1 & 2 - Phase II studies in renal cancer therapy (TLX250) Advance three additional therapeutic assets to the point they are ready to undertake a pivotal trial: • • . TLX101: Brain cancer (glioblastoma) TLX66: Phase II study in SALA (amyloidosis) TLX250: In an additional rare indication (not yet disclosed) Expand diagnostic portfolio including TLX101-CDx for brain cancer, TLX599-CDx (PSMA-SPECT) and Scintimun (bone marrow conditioning) outside of the EU Future pipeline development including targeted alpha therapy Operational costs and working capital requirements will be funded from existing cash plus future revenues Source of Funds Placement Share Purchase Plan Note: assumes SPP is fully subscribed TOTAL Use of Funds TELIX PHARMACEUTICALS A$m 175 25 200 Tx/Dx A$m Prostate (TLX591) clinical studies Tx Kidney (TLX250) clinical studies Brain (TLX101) clinical study Bone marrow conditioning (TLX66) clinical study (Tx) and Dx commercialisation Future pipeline and indication expansion Capital raise costs TOTAL 90 30 90 5 Tx 30 Tx Dx + Tx 5 Tx 37 Dx 25 8 200 Telix Pharmaceuticals Limited (ASX: TLX) 11

View entire presentation